Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
Top Cited Papers
Open Access
- 1 October 2014
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 76 (6), 802-812
- https://doi.org/10.1002/ana.24286
Abstract
Objective The increased risk of progressive multifocal leukoencephalopathy (PML) with natalizumab treatment is associated with the presence of anti–JC virus (JCV) antibodies. We analyzed whether anti-JCV antibody levels, measured as index, may further define PML risk in seropositive patients. Methods The association between serum or plasma anti-JCV antibody levels and PML risk was examined in anti-JCV antibody–positive multiple sclerosis (MS) patients from natalizumab clinical studies and postmarketing sources. For PML and non-PML patients, the probabilities of having an index below and above a range of anti-JCV antibody index thresholds were calculated using all available data and applied to the PML risk stratification algorithm. Longitudinal stability of anti-JCV antibody index was also evaluated. Results Anti-JCV antibody index data were available for serum/plasma samples collected >6 months prior to PML diagnosis from 71 natalizumab-treated PML patients and 2,522 non-PML anti-JCV antibody–positive patients. In patients with no prior immunosuppressant use, anti-JCV antibody index distribution was significantly higher in PML patients than in non-PML patients (p < 0.0001). Among patients who were anti-JCV antibody negative at baseline in the AFFIRM and STRATIFY-1 trials, 97% remained consistently negative or below an index threshold of 1.5 over 18 months. Retrospective analyses of pre-PML samples collected longitudinally from PML patients displayed sustained higher anti-JCV antibody index over time. Interpretation Anti-JCV antibody levels in serum/plasma, measured as index, may differentiate PML risk in anti-JCV antibody–positive MS patients with no prior immunosuppressant use. Continued evaluation of anti-JCV antibody index and PML risk is warranted. Ann Neurol 2014;76:802–812Keywords
This publication has 31 references indexed in Scilit:
- JC Viremia in Natalizumab-Treated Patients with Multiple SclerosisNew England Journal of Medicine, 2013
- JC virus antibody status underestimates infection ratesAnnals of Neurology, 2013
- Changes to anti-JCV antibody levels in a Swedish national MS cohortJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathyArchiv für die gesamte Virusforschung, 2012
- Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titerMedical Microbiology and Immunology, 2011
- BK virus antibody titers and intensity of infections after renal transplantationJournal of Clinical Virology, 2008
- Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathologyThe Journal of Experimental Medicine, 2008
- Immunoglobulin G, A, and M Responses to BK Virus in Renal TransplantationClinical and Vaccine Immunology, 2006
- Genetic variability in BK Virus regulatory regions in urine and kidney biopsies from renal-transplant patientsJournal of Medical Virology, 2006
- Positive Correlation between Epstein-Barr Virus Viral Load and Anti-Viral Capsid Immunoglobulin G Titers Determined for Hodgkin's Lymphoma Patients and Their RelativesJournal of Clinical Microbiology, 2006